HE 2400
Latest Information Update: 24 Apr 2007
At a glance
- Originator Virginia Commonwealth University
- Class Antineoplastics
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 05 Jun 2003 Preclinical trials in Cancer in USA (unspecified route)